The American Heart Association and American College of Cardiology (AHA/ACC), in collaboration with ACCP and the Heart Rhythm Society (HRS), have released the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. ACCP thanks Kazuhiko Kido, Pharm.D., Ph.D., M.Sc., BCCP, BCPS, who served as the ACCP representative on the writing panel. Kido is a clinical assistant professor at West Virginia University School of Pharmacy and a clinical pharmacy specialist in advanced heart failure and pulmonary hypertension at the West Virginia Medicine Ruby Memorial Hospital Heart and Vascular Institute.

The College also wishes to congratulate two ACCP members who were appointed by the AHA/ACC Joint Committee for inclusion on the writing panel on the basis of their therapeutic expertise and engagement in both of these organizations: Anastasia L. Armbruster, Pharm.D., FACC, BCPS, associate professor in the Department of Pharmacy Practice at the University of Health Sciences and Pharmacy in St. Louis; and James E. Tisdale, Pharm.D., FCCP, FAPhA, FNAP, FAHA, FACC, BCPS, professor in the Department of Pharmacy Practice at the Purdue University College of Pharmacy and adjunct professor in the Indiana University School of Medicine. ACCP appreciates the work of all members of the writing panel in updating this treatment guideline and their dedication to optimizing the care of patients with atrial fibrillation.